natgillin/translations-raw huggingface dataset:
(a8) an antigen-binding site comprising the of H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of zSEQ ID NOs: 96, 97, and 98, respectively; 
(a8) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 96, 97 odnosno 98 (H-lanac CDR-područja od Q405);
In an embodiment which is fit for manufacturing a bridge deck, said upstanding structure may comprise at least two generally parallel rims of a bendable nature. 
Sustav kalupa u skladu s patentnim zahtjevom 1, pri čemu uspravna struktura (2) obuhvaća najmanje dva uglavnom paralelna ruba (6) savitljive prirode.
c') reducing the imine group using a reducing agent comprising a triacetoxyborohydride moiety to form an antigen-linker; and 
c’) reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugat antigen-spojnica; i
using the nucleosome associated DNA base level detected to identify the disease status of the subject, wherein the DNA base is selected from: uracil, inosine, xanthine, hypoxanthine or a modified base, wherein the disease is selected from: cancer, cardiomyopathy, systemic lupus erythematosus, colitis, chronic obstructive pulmonary disorder, Crohn's disease and rheumatoid arthritis. 
(li) korištenje otkrivene osnovne razine DNK povezane s nukleosomom za identifikaciju statusa bolesti kod subjekta, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina, pri čemu je bolest odabrana od: raka, kardiomiopatije, sistemskog eritematoznog lupusa, kolitisa, kroničnog opstruktivnog plućnog poremećaja, Crohnove bolesti i reumatoidnog artritisa.
A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: 
Derivat pirimidona prikazan formulom (I), ili njegova sol, ili njegov solvat ili njegov hidrat:
converting the suspension of step (1) into particulate form; 
(2) prevođenja suspenzija iz koraka (1) u partikularni oblik;
Glutamine may preferably be added to the medium during cell culture (e.g. 
Preporučljivo je da se glutamin doda mediju tijekom uzgoja stanica (pr.
As shown in Figure 2A, the container 101 is resting on external ridges 102. 
Kako je prikazano na Slici 2A, posuda 101 stoji na vanjskim izbočenjima 102.
hydrogen, substituted or unsubstituted alkyl, 
(b) supstituirani ili nesupstituirani alkil.
LAL, TOG, Bio Burden and pH indicate whether the system is clean or not. 
LAL, TOC, biološko opterećenje 1 pH pokazuju da li je sustav čist ili nije.
A compound having the formula an N -oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein Q is Ar2, R6a, pyrrolidinyl substituted with R6, piperidinyl substituted with R6 or homopiperidinyl substituted with R6; 
Spoj koji ima formulu [image] njegov N-oksid, adicijska sol, kvaternarni amin, metalni kompleks ili stereokemijski izomerni oblik naznačen time da Q je Ar2, R6a, pirolidinil supstituiran sa R6, piperidinil supstituiran sa R6 ili homopiperidinil supstituiran sa R6;
or a pharmaceutically acceptable salt thereof, under standard Mitsunobu reaction conditions to form the compound of formula (7), or a pharmaceutically acceptable salt thereof. 
<I ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7), ili njegovu farmaceutski prihvatljivu sol.
The data sheet shown in Figure 3 is produced as described in Figure 2. 
List za podatke, koji je prikazan na slici 3, izrađen je kao što je opisano uz sliku 2.
Number of subjects 
Broj međunarodne prijave:
Embodiments of the present invention include those compounds wherein R4 is phenyl substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, (C1-3)alkoxy, phenyl(C1-3)alkoxy, hydroxy, C1-6alkylaminocarbonyl, and aminocarbonyl; provided that no more than one R41 substitutent is aminocarbonyl, C1-6alkylaminocarbonyl, hydroxy, or a phenyl-containing substituent. 
Spoj prema zahtjevu 1 naznačen time da R" je fenil supstituiran sa jednim do tri R"' supstituenta nezavisno izabrana iz skupine koju čine (Crs)alkil, (Crg)alkoksi, feni(C,.)alkoksi, hidroksi, C,salkilaminokarbonil i aminokarbonil; uz uvjet da ne više od jedan R"' supstituent je aminokarbonil, C, galkilaminokarbonil, hidroksi ili supstituent koji sadrži fenil.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 214, 196, 202, 210, 213, 217 and 223 in which 1 or 2 amino acids are substituted, or added, wherein said peptide induces a cytotoxic T cell specific to a cell expressing KNTC2. 
Peptid koji može inducirati citotoksične T-stanice u skladu s patentnim zahtjevom 2, gdje se navedeni peptid sastoji od aminokiselinskog slijeda kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34 1 358, u kojem 1 ili 2 aminokiseline su zamijenjen ili dodan, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
attaching the optical element to the adhesive on the glass pane; and 
- pričvršćivanjem optičkog elementa na ljepilo na staklenom oknu; i
The take off board is an extension of the bottom of the hive. 
Skidanjem daske rasteže se dno košnice.
wall, roof, ceiling, floor or profiles, e.g. 
zid, krov, strop, pod ili pročelje, npr.
A combination for use according to any one of claims 1 to 3, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797,KUL-1248,TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je 2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)- formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1; the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO:2;; 
(iv) sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO: 1; (v) sekvencu amino kiseline od receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2;
The cell according to Claim 7, wherein the cell is a Chinese Hamster Ovary (CHO) cell. 
Stanica prema zahtjevu 9, naznačena time, što stanica jeste stanica jajnika kineskog hrčka (engl. Chinese Hamster Ovary; CHO).
submerging one or more roe sacks in oil derived from sturgeon roe sack membrane in accordance with any of claims 1 to 4, preferably at refrigerated temperature, in a container suitable for vacuum packing such that the roe sacks are completely covered by said oil; 
(i) - potapanje jednog ili više jajnika u ulje dobiveno od membrane jajnika jesetre sukladno bilo kojem od zahtjeva 1 do 4, poželjno na temperaturi hladnjaka, u spremniku prikladnom za vakuumsko pakiranje tako da su jajnici potpuno pokriveni navedenim uljem;
The method of claim 5, wherein the endoparasite is a helminth selected from the group consisting of Ostertagia, Haemonchus, and mixtures thereof wherein said helminth is resistant to macrolide antibiotics when not administered by the method of claim 5 . A liquid long acting injectable formulation for combating ectoparasites and/or endoparasites in a mammal comprising: 
Tekuća injektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da endoparazit je helmint odabran iz skupine koju čine: Ostertagia, Haemonchus i njihove kombinacije, pri čemu je helmint otporan na makrolidne antibiotike ako nisu primjenjeni u skladu sa zahtjevom 8.
It is thus becoming a widely held view in the medicinal chemistry field that drugs capable of blocking the pre-synaptosomal uptake of serotonin in the brain, thereby alleviating serotonin abnormalities at adjacent pest-synaptic receptor sites, will comprise an additional major category of antidepressant agents. 
Tako je postalo široko prihvaćeno gledište u medicinskoj kemiji da će lijekovi koji mogu blokirati presinaptosomalnu potrošnju serotonina, pa tako ublažavaju abnormalnosti serotonina na susjednim postsinaptičkim reccptorski mjestima, činiti dopunsku glavnu kategoriju antidepresivnih sredstava.
The pharmaceutical composition of any one of claims 1 to 11, wherein said CD3 binding domain is a bispecific single chain antibody 
Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedena CD3 vezna domena bispecifično jednolančano protutijelo.
a system adapted to remotely transmit data being external to the control unit and designed to communicate by carrier current with the data collecting unit, the remote data transmission unit comprising a modem adapted to remotely send the data collected by the data collecting unit and received by the control unit; and 
sustav za daljinski prijenos podataka (88), pri čemu je sustav vanjski do upravljačke jedinice (80) i predviđen je za komuniciranje struje nosača s uređajem za prikupljanje podataka, te sustav za daljinski prijenos podataka (88) sadrži modem za daljinsko slanje podataka prikupljenih uređajem za skupljanje i koje prima upravljačka jedinica (80) .
a third nucleic acid molecule encoding a 3rd CH3 domain-comprising polypeptide chain, and a fourth nucleic acid molecule encoding a 4th CH3 domain-comprising polypeptide chain, wherein at least two of said nucleic acid molecules are provided with means for preferential pairing of said 1st and 2nd CH3 domain-comprising polypeptides and said 3rd and 4th CH3-domain comprising polypeptides, said method further comprising the step of culturing said host cell and allowing for expression of said at least four nucleic acid molecules and harvesting said at least two different Ig-like molecules from the culture. 
druge molekule nukleinske kiseline koja kodira drugi polipeptidni lanac koji sadrži CH3 domenu humanog IgG, koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavu numeracije, c. = treće molekule nukleinske kiseline koja kodira treći polipeptidni lanac koji sadrži CH3 domenu i d. četvrte molekule nukleinske kiseline koja kodira četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni postupak dalje sadrži korak kultivacije navedene stanice domaćina i omogućavanja ekspresije navedena najmanje četiri molekule nukleinske kiseline i sakupljanja navedena najmanje dva različita antitijela iz kulture.
CRL-9096] or compared to a sialylation deficient cell line such as NM-F9 and NM-D4. it comprises no detectable NeuGc it comprises no detectable Galalpha1-3Gal 
CRL-9096 (CHOdhfr-) ili u usporedbi sa sijalilacijski deficijantnom staničnom linijom, poput DSM ACC2606 (NM-F9) i DSM ACC2605 (NM- D4); ili
These new combinations present significant therapeutic advantages with respect to the combinations of M3 antagonists and a corticosteroid already known in the art. 
Navedene nove kombinacije odlikuju značajne terapijske prednosti u odnosu na kombinaciju M3 antagonista 1 B2-agonista poznatih iz stanja tehnike.
The solid pharmaceutical composition according to claim 1, comprising two lipophilic active compounds, preferably fenofibrate and atorvastatin, both positioned in intimate contact with the polymeric matrix, wherein said polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the lipophilic drugs, said matrix being preferably formed by two polymers, one of the polymers is an amphiphilic polymer, preferably Poloxamer 407, and the other polymer is a hydrophilic polymer, preferably sodium carboxymethylcellulose, sodium alginate or chitosan. 
Kruti farmaceutski pripravak prema zahtjevu 1, koji sadrži dva lipofilna aktivna spoja, poželjno fenofibrat i atorvastatin, oba smještena u bliskom kontaktu s polimernom matricom, pri čemu navedena polimerna matrica nije poprečno povezana 1 ne dolazi do kovalentne interakcije između dva ili više polimera i između polimera i lipofilnih lijekova, navedena je matrica poželjno načinjena od dva polimera, jedan od polimera je amfifilni polimer, poželjno Poloksamer 407, a drugi polimer je hidrofilni polimer, poželjno natrijeva karboksimetilceluloza, natrijev alginat ili hitozan.
that the above-mentioned mechanism consists of a pivot arm connecting, one the one hand, to the rear side of the lock-up body and, on the other hand, is supported by means of a support portion, such as a support collar 78. 
- ranije spomenuti mehanizam sastoji se od pivot ruke spojene, s jedne strane, na stražnju stranu tijela za zaključavanje, i, s s druge strane, poduprta je pomoću dijela za potporu, poput potpornog ovratnika (78).
□ if a DMR data/signalling/call set-up individual feature is recognized, send a MESSAGE message to a DMR Gateway to be involved, and 
DMR = podatkovno/signalizacijsko/obilježje za uspostavu poziva prepoznato, šalje MESSAGE/PORU KA poruku ulazu DMR koji će biti uključen, i
The pharmaceutical composition of Claim 3, wherein the polymorph of Formula I is present from 75% to 99.99% of the total weighty, and wherein the pharmaceutical composition is in a solid dosage form. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u od 75% do 99,99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
A granulate according to claim 12 having the following composition: gabapentin 
Granulat prema zahtjevu 12, naznačen time što ima sljedeći sastav: gabapentin
as hopper (5) tapering to a discharge outlet (6), said hopper being placed inside the vessel (2), and 
- lijevak (5), koji se sužava prema izlazu za pražnjenje (6), gdje navedeni lijevak se stavlja u posudu (2), i
An inhaler according to claim 1, wherein the medicament is selected from the group consisting of salbutamol, formoterol, salmeterol, fluticasone, budesonide, beclomethasone, tiotropium, ipratropium and combinations thereof. An inhaler according to claim 7, wherein the medicament delivery port is arranged at an opposite end of the elongated body to the end face. 
Inhalator u skladu s patentnim zahtjevom 7, pri čemu je lijek odabran iz grupe koja se sastoji od protuupalnih agenasa, antikolinergičkih agenasa, agonista f2-adrenoreceptora, protuinfektivnih agenasa, antihistaminika i njihovih kombinacija, poželjno gdje je lijek odabran iz grupe koja se sastoji od salbutamola, formoterola, salmeterola, flutikazona, budezonida, beklometazona, tiotropija, ipratropija i njihovih kombinacija.
The heat engine of claim 10, further comprising a positive displacement decompressor configured to provide a pressure gradient through which the refrigerant in the gaseous phase flows continuously from the high-pressure zone to the low-pressure zone, the positive displacement decompressor configured to maintain a pressure differential between the high-pressure zone and the low-pressure zone of between 20 bar and 42 bar, the positive displacement decompressor configured to extract mechanical energy due to the pressure gradient. 
Toplinski motor prema Zahtjevu 9, koji dalje sadrži kompresor (208) s pozitivnim izmještanjem koji je konfiguriran da omogući gradijent tlaka pomoću kojeg rashladno sredstvo u plinovitoj fazi kontinuirano teče iz zone visokog tlaka do zone niskog tlaka, gdje je kompresor s pozitivnim izmještanjem konfiguriran da zadrži razliku tlaka između zone visokog tlaka i zone niskog tlaka od između oko 20 bara i oko 42 bara, gdje je kompresor s pozitivnim izmještanjem konfiguriran da vrši ekstrahiranje mehaničke energije uslijed gradijenta tlaka.
is either cyano or chlorine. as well as its tautomers, stereoisomers and salts. 
R? je cijano ili klor, kao i njegovi tautomeri, stereoizomeri i soli.
-16.8 ± 0.2 degrees 2theta. The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 1, which is polymorph 2 and has at least reflection in an X-ray powder diffractogram using CuKa1 radiation at 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 1, naznačen time da je polimorf 2 i ima refleksiju u difraktogramu X-zraka na prahu korištenjem CuKa1 zračenja barem kod 8.1, 15.8 i 16.5 stupnjeva 2theta ± 0.2 stupnjeva 2theta.
admixing an oil with water to form a fuel comprising an emulsion; 
* - primješavanje ulja sa vodom da se dobije gorivo koje sadrži emulziju;
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje kad je testiran u komparativnoj kliničkoj studiji je bioekvivalentan trgovačkom proizvodu OxyContin"".
In certain cases, a human antibody may be at least 60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene. Typically, a recombinant human antibody will display no more than 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene in the VH or VL framework regions. 
Izolirano monoklonalno protutijelo ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilno područje jakog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% 1li 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:7; 1 varijabilno područje slabog lanca, koje ima najmanje 80%, 90%, 95%, 97%, 98% ili 99% identiteta sekvence prema aminokiselinskoj sekvenci od SEQ ID NO:8.
Suitably the laser beam may have a power less than 20W, typically 4 - 10W, e.g. typically nominally 8W. Suitably the laser beam may have a wavelength of nominally 980nm. 
Poželjno je da laserski snop može imati snagu manju od 20 W, tipično 4 - 10 W, na primjer, normalno 8 W. Poželjno je da laserski snop ima valnu nominalnu duljinu 980 nm.
Alternative approaches to these cytotoxic anti-tumour agents are currently being developed, for example selective inhibitors of cell signalling pathways. 
Trenutno se razvijaju alternativni pristupi ovim citotoksičnim, anti-tumorskim agensima, primjerice selektivni inhibitori stanične signalizacije.
This additional isolation step of the other diastereoisomeric salt comprises the concentration of the mother liquor generated upon isolating the first diastereoisomeric salt and the subsequent crystallization so as to cause precipitation of the said other diastereoisomeric salt. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se dodatno izdvajanje druge dijastereoizomerne soli formule (IT) sastoji u koncentriranju matičnog luga dobivenog prilikom izdvajanja prve dijastereoizomerne soli i kristalizacije nakon toga kako bi se dobilo navedenu drugu dijastereoizomernu sol.
The crude mixture was poured onto a plug of silica gel and the product was eluted with ethyl acetate-heptane (1:2) to give 3.2 g (100%) of (2-mercapto-benzyl)-methyl-carbamic acid tert-butyl ester contaminated with traces of triisopropylsilane fluoride. Example 4 
Gruba smjesa izlita je na čep od dilikonskog gela i proizvod je ELUTED s etil acetat-heptanom (1:2) kako bi se dobilo 3.2 (100%) (2-merkapto-benzil)- metil-karbamska kiselina tert-butil estera kontaminiranog s triizopropilsilan fluoridom u tragovima.
A pharmaceutical composition comprising Form I of claim 1, and a pharmaceutically acceptable carrier. 
22. Farmaceutska smjesa koja sadrži Oblik I iz zahtjeva 1, i farmaceutski prihvatljiv nosač.
2-Chloro-5-bromobenzoyl chloride was readily prepared from commercially available 2-chloro-5-bromobenzoic acid by treatment with oxalyl chloride in a solvent, such as CH2Cl2, containing a catalytic amount of DMF. 
2-kloro-5-bromobenzoil klorid je jednostavno pripremljen od komercijalno dostupne 2-kloro-5-bromobenzoeve kiseline tretmanom sa oksalil kloridom u otapalu, kao što je CH2CL, koji sadrži katalitičku količinu DMF.
Method according to claim 1, wherein said preparing comprises adding said alkaline silicate in a weight percentage comprised between 89.9% and 99.7%. 
Metoda prema zahtjevu 1, pri čemu se navedena priprema sastoji od dodavanja navedenog _alkalnog silikata u masenom udjelu obuhvaćenom između 89,9% i 99,7%.
the first fragment is a C . difficile toxin A repeating domain fragment; 
prvi fragment je fragment ponavljane domene toksina A i sadrži najmanje 100 aminokiselina;
According to various embodiments, the tops 1002, 1603 of the container cap 1500, 1600 and the sidewalls 1503, 1604 are generally perpendicular to one another. 
Prema raznim ostvarenjima, gornje površine 1002, 1603 poklopaca 1500, 1600 posude i bočne stijenke 1503, 1604 obično su okomite jedna prema drugome.
All drug doses were calculated as base equivalent weight. Statistical Analysis 
Sve doze lijekova su proračunate kao ekvivalent težine. Statističke analize
A human engineered DKK-1 antibody for use according to any one of claims 1 to 3, wherein the human engineered DKK-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20. 
Konstruirano protutijelo protiv DKK-1 u skladu s patentnim zahtjevom 1, naznačen time što konstruirano protutijelo protiv DKK-1 sadrži teški lanac, koji ima aminokiselinski slijed SEQ ID NO: 18 i laki lanac, koji ima aminokiselinski slijed SEQ ID NO: 20.
A power point comprising: 
Točka napajanja, koja sadrži:
A method for treating diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), nonalcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 . 
Spoj prema zahtjevu 1, za uporabu u liječenju dijabetesa, metaboličkog sindroma, pretilosti, bolesti jetre, steatpze jetre, ne-alkoholne masne bolesti jetre (NAFLD), ne-alkoholnog steato-hepatitisa (NASH), fibroze jetre, dislipidemije, hipertrigliceridemije, hiperkolesterolemije, upale, raka, kardiovaskularne bolesti, ateroskleroze, visokog krvnog tlaka, retinopatija ili neuropatija.
emission means (6, 7, 8, 9) for emitting infrared radiation, to dry out the walls and / or objects contained in the room, the emission means comprising: 
sredstva za emisiju (6, 7, 8, 9) za emisiju infracrvenog zračenja, kako bi se osušilo zidove i / ili predmete u prostoriji, sredstva za emisiju obuhvaćaju:
reading the pixels of said at least one image into a series of blocks of predetermined size, 
(b) očitavanje piksela spomenute barem jedne slike u spoj čvorova predodređene veličine,